Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 10/20 | 0.46 |
| ▸ | AXL | P30530 | 9/20 | 0.44 |
| ▸ | FLT3 | P36888 | 9/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28922912 | 0.98 | KEAP1 (0.66) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL24484881 | 0.85 | KEAP1 (0.64) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL21099155 | 0.81 | KEAP1 (0.58) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL14554770 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL2535366 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL25804613 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL14638413 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL24494597 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL6092812 | 0.81 | KEAP1 (1.00) | KEAP1DYRK1AMEN1CYP1A2KMT2A | |
| SCHEMBL2049672 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1AMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12022728-B2 | Organic electroluminescent element and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2024-06-25 | — | — | US | disclosed |
| WO-2023227696-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20070132372-A1 | AMINE BASED COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070134511-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070111028-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070103065-A1 | Organic electroluminescent device and display using same | IDEMITSU KOSAN CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070088185-A1 | Anthrylarylene derivative, material for organic electroluminescence device and organic electroluminescence device using same | IDEMITSU KOSAN CO., LTD. (JP) | 2007-04-19 | — | — | US | disclosed |
| US-20070063638-A1 | White color organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070029927-A1 | AROMATIC AMINE DERIVATIVES AND ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070013296-A1 | Biphenyl derivative, material for organic electroluminescence device, and organic electroluminescence device using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2007-01-18 | — | — | US | disclosed |
| US-20070007882-A1 | Organic electroluminescent device and display using same | IDEMITSU KOSAN CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | KEAP1 887/4885DYRK1A 4733/4885MEN1 479/4885 |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | KEAP1 3507/4885DYRK1A 2496/4885MEN1 1500/4885 |
| US-20070132372-A1 | AMINE BASED COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | KCNH2, SLC7A5, KCNH3 | KEAP1 1057/4885DYRK1A 678/4885MEN1 1092/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | KEAP1 170/4885DYRK1A 2685/4885MEN1 4442/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KEAP1 1968/4885DYRK1A 3476/4885MEN1 150/4885 |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | KEAP1 1704/4885DYRK1A 4004/4885MEN1 3868/4885 |
| US-20070111028-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | EML4, TYR, OCIAD2 | KEAP1 3197/4885DYRK1A 166/4885MEN1 2266/4885 |
| US-20070088185-A1 | Anthrylarylene derivative, material for organic electroluminescence device and organic electroluminescence device using same | RABGGTA, ALAD, GCDH | KEAP1 2838/4885DYRK1A 1301/4885MEN1 3242/4885 |
| US-20070029927-A1 | AROMATIC AMINE DERIVATIVES AND ELECTROLUMINESCENCE DEVICE USING THE SAME | TYR, MAOA, MAOB | KEAP1 1627/4885DYRK1A 786/4885MEN1 1697/4885 |
| US-12022728-B2 | Organic electroluminescent element and electronic device | L1CAM, ESR1, LEF1 | KEAP1 693/4885DYRK1A 4125/4885MEN1 635/4885 |
| US-20070013296-A1 | Biphenyl derivative, material for organic electroluminescence device, and organic electroluminescence device using the same | EED, BMI1, EBPL | KEAP1 734/4885DYRK1A 2225/4885MEN1 2736/4885 |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | KEAP1 428/4885DYRK1A 495/4885MEN1 1359/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KEAP1 1968/4885DYRK1A 3476/4885MEN1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.